白念珠菌耐药的分子机制研究进展  

Molecular Resistance Mechanisms of Candida albicans to Antifungal Agents

作　　者：乔建军[1] 刘伟[1] 李若瑜[1] 

机构地区：[1]北京大学第一医院皮肤科北京大学真菌和真菌病研究中心,北京100034

出　　处：《微生物学通报》2007年第2期393-396,共4页Microbiology China

基　　金：国家自然科学基金(No30500027);教育部留学归国人员科研启动基金资助

摘　　要：近年来,免疫受损人群不断增多,该人群念珠菌病发病率呈上升趋势。随着抗真菌药物的广泛应用,临床分离到的白念珠菌耐药株增多,有关白念珠菌对抗真菌药物的耐药机制的研究又有了进一步的进展。就白念珠菌对唑类、多烯类、5-氟胞嘧啶、棘白菌素类等抗真菌药物的耐药机制方面的研究进展,作了介绍。In recent years, with the increasing of immunocompromised patients in clinical practice, invasive candidiasis has been increased accordingly. Although several antifungal drugs, including polyenes, azoles, 5-flucytosine, and echinocandins, have been used widely to treat invasive candidiasis, the treatment failure that caused by the resistance of Candida albicans to these antifungal drugs have been reported widely. Here, we reviewed the molecular mechanisms of resistance to asoles, polyenes, 5-flucytosine, and echinocandins, such that to provide an update on these issues.

关 键 词：白念珠菌 抗真菌药物 耐药 

分 类 号：R379[医药卫生—病原生物学]